#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Kawasaki's disease Chronic lymphocytic leukaemia refractory Pancreatic neuroendocrine tumour Chondrosarcoma Sexually transmitted disease Hyperinsulinaemic hypoglycaemia Plasma cell myeloma refractory Adrenocortical carcinoma Rett syndrome Paraneoplastic neurological syndrome Microvillous inclusion disease Osteogenesis imperfecta Ewing's sarcoma recurrent Von Hippel-Lindau disease Ischaemic stroke More trials…

    Learn about Rare Diseases

    Glycogen storage disease type I – Diagnostics Mitochondrial myopathy – Diagnostics Rhabdomyosarcoma – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Extranodal marginal zone B-cell lymphoma (MALT type) – Trials in Disease Ewing’s sarcoma – Diagnostics Leiomyosarcoma recurrent – Life with Disease Haemolytic uraemic syndrome – Diagnostics Splenic marginal zone lymphoma – Trials in Disease Mantle cell lymphoma stage III – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gallium (68Ga) Chloride Nms-03592088 Omp10 Sodium Zirconium Cyclosilicate Irbesartan Fingolimod L-METHIONINE Pentetic Acid Batoprotafib Munc-Cd34 Loncastuximab Tesirine Gtaexs617 Ipratropium Bromide Enfuvirtide Amniotic Membrane, Human Tenecteplase Ralinepag Clopidogrel Dexrazoxane Hydrochloride Colchicine More therapies…

    Learn about Your Condition

    Haemorrhoids Septic shock Chronic spontaneous urticaria Necrotising myositis Medulloblastoma Nicotine dependence Acute cardiac event Iron deficiency anaemia Chordoma Actinic keratosis Craniotomy Anogenital warts Prostate cancer metastatic Stress urinary incontinence Osteosarcoma metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Colitis ulcerative

  • Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

    Recruiting

    2 1
    Czechia Italy Poland

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Croatia Czechia France Greece Hungary Italy +5

  • A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    France Germany Greece Italy The Netherlands Poland

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9
1 2 3 … 20
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!